These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 26350388)

  • 1. Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial.
    Li P; Yang Y; Chen T; Liu Y; Cao A; Liu J; Wang Z; Zhao X; Qin Y; Ma L
    Sci Rep; 2015 Sep; 5():13789. PubMed ID: 26350388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
    Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
    J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Modifying Antiplatelet Treatment to Ticagrelor in High-Risk Coronary Patients With Low Response to Clopidogrel (MATTIS).
    Musallam A; Orvin K; Perl L; Mosseri M; Arbel Y; Roguin A; Lev EI
    Can J Cardiol; 2016 Oct; 32(10):1246.e13-1246.e19. PubMed ID: 26971236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome.
    Paarup Dridi N; Johansson PI; Lønborg JT; Clemmensen P; Radu MD; Qayyum A; Pedersen F; Kollslid R; Helqvist S; Saunamäki K; Kelbæk H; Jørgensen E; Engstrøm T; Holmvang L
    Platelets; 2015; 26(6):521-9. PubMed ID: 25166751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Antiplatelet Effects of Once and Twice Daily Low-Dose Ticagrelor and Clopidogrel After Percutaneous Coronary Intervention.
    Choi KN; Jin HY; Shin HC; Park YA; Seo JS; Jang JS; Yang TH; Kim DK; Kim DS
    Am J Cardiol; 2017 Jul; 120(2):201-206. PubMed ID: 28554486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study.
    Jeong KH; Cho JH; Woo JS; Kim JB; Kim WS; Lee TW; Kim KS; Ihm CG; Kim W
    Am J Kidney Dis; 2015 Jun; 65(6):916-24. PubMed ID: 25622774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
    Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
    J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of Ticagrelor and Double-Dose Clopidogrel Based on Platelet Reactivity Determined by VerifyNow-P2Y12 for Chinese Subjects After Elective PCI.
    Wu X; Liu G; Lu J; Zheng XX; Cui JG; Zhao XY; Huang XH
    Int Heart J; 2017 Apr; 58(2):167-173. PubMed ID: 28321022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity.
    Bonello L; Laine M; Baumstarck K; Fernandez J; Maillard L; Peyrol M; Bessereau J; Aradi D; Camilleri E; Roubille F; Piot C; Paganelli F; Camoin-Jau L; Dignat-George F
    Int J Cardiol; 2013 Oct; 168(4):4244-8. PubMed ID: 23911273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study.
    Waksman R; Maya J; Angiolillo DJ; Carlson GF; Teng R; Caplan RJ; Ferdinand KC
    Circ Cardiovasc Interv; 2015 Jul; 8(7):e002232. PubMed ID: 26152562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study.
    Bernlochner I; Mayer K; Orban M; Morath T; Jaitner J; Rössner L; Gross L; Laugwitz KL; Kastrati A; Sibbing D
    Platelets; 2016 Dec; 27(8):796-804. PubMed ID: 27275651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
    Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction.
    Ahn SG; Lee SH; Yoon JH; Kim WT; Lee JW; Youn YJ; Ahn MS; Kim JY; Yoo BS; Yoon J; Choe KH
    JACC Cardiovasc Interv; 2012 Mar; 5(3):259-67. PubMed ID: 22440490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel.
    Alexopoulos D; Xanthopoulou I; Davlouros P; Plakomyti TE; Panagiotou A; Mavronasiou E; Hahalis G
    Am Heart J; 2011 Oct; 162(4):733-9. PubMed ID: 21982667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention.
    Bonello L; Laine M; Thuny F; Paganelli F; Lemesle G; Roch A; Kerbaul F; Dignat-George F; Berbis J; Frere C
    Int J Cardiol; 2016 Aug; 216():190-3. PubMed ID: 27179310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How Long Does It Take for Clopidogrel and Ticagrelor to Inhibit Platelets in Patients Undergoing Primary Percutaneous Coronary Intervention? A Detailed Pharmacodynamic Analysis: Time Course of Platelet Reactivity in STEMI (TOPS).
    Bergmeijer TO; Godschalk TC; Janssen PWA; Berge KVD; Breet NJ; Kelder JC; Hackeng CM; Ten Berg JM
    Semin Thromb Hemost; 2017 Jun; 43(4):439-446. PubMed ID: 28561235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
    Storey RF; Angiolillo DJ; Patil SB; Desai B; Ecob R; Husted S; Emanuelsson H; Cannon CP; Becker RC; Wallentin L
    J Am Coll Cardiol; 2010 Oct; 56(18):1456-62. PubMed ID: 20832963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
    Parodi G; Bellandi B; Valenti R; Migliorini A; Marcucci R; Carrabba N; Giurlani L; Gensini GF; Abbate R; Antoniucci D
    Am Heart J; 2014 Jun; 167(6):909-14. PubMed ID: 24890542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, Double-Blind, Active Comparator Pharmacodynamic Study of Platelet Inhibition with Crushed and Integral Formulations of Clopidogrel and Ticagrelor in Acute Coronary Syndrome.
    Perla HT; Thomson VS; Attumalil TV; Geevar T; Alex AG; Dave RG; Nair SC; Gowri SM; Mony PK; George P; Joseph G
    Am J Cardiovasc Drugs; 2023 Jul; 23(4):455-466. PubMed ID: 37351814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.